EXT1 Genotype

If you or a close relative started developing several hard, painless lumps near the joints during childhood, a change in this gene is the single most likely genetic explanation. Knowing whether you carry it answers why the growths appear and whether your children could inherit the same tendency.

This is a once-in-a-lifetime test, because the result never changes. Its value comes from what you do with it over the years: how closely to watch for complications, when to involve a specialist, and what to tell your biological family.

What This Gene Does in Your Body

EXT1 (exostosin-1) sits on chromosome 8 and carries the recipe for a builder enzyme that works inside a cell's packaging center. Together with a partner enzyme made by a second gene called EXT2, it assembles heparan sulfate, a sugar chain that coats the outside of cells and helps steer the signals that tell cartilage and bone how and where to grow.

When EXT1 works poorly, cells make less heparan sulfate, and the growth signals near the ends of long bones (the growth plates) get scrambled. Cartilage ends up forming in the wrong places and hardens into cartilage-capped bony growths. The condition follows an autosomal dominant pattern, which means a single changed copy inherited from one parent is enough to cause it.

Most disease-causing changes in this gene are loss-of-function variants: nonsense, frameshift, splice-site, or larger deletion changes that shut the gene down rather than subtly alter it. A smaller number are missense changes, which swap a single building block and often leave some working enzyme behind.

The Condition It Signals: Multiple Osteochondromas

The main disorder tied to this gene is hereditary multiple osteochondromas, also called hereditary multiple exostoses, a childhood-onset skeletal condition in which several benign bony growths appear near the growth plates. Complications can include pain, limited joint movement, limb-length differences, deformity, and occasional pressure on nearby nerves or blood vessels.

Across studied groups, a change in EXT1 or EXT2 is found in roughly 70 to 95 percent of affected people, and EXT1 accounts for about 65 percent of the cases that get a molecular answer. Testing confirms the diagnosis, identifies which of the two genes is involved, and pinpoints the exact family variant so relatives can be checked.

Why an EXT1 Result Often Points to Heavier Bone Disease

On average, people with an EXT1 change tend to have a heavier disease burden than those with an EXT2 change: more growths, shorter stature, more deformity, and more surgeries. In a study of 529 people with the condition, carrying an EXT1 change was linked to being nearly seven times as likely to fall into the severe category (odds ratio 6.817), though the estimate was imprecise given how few of the mildest patients carried it (95% confidence interval 1.003 to 46.348).

A separate study of 43 patients found the average clinical severity score was about 40 percent higher in the EXT1 group than the EXT2 group (5.76 versus 4.06). Earlier family-based work pointed the same direction, with EXT1-linked patients undergoing more operations and facing a higher chance of limb shortening.

This is not a good-gene versus bad-gene story with a fixed outcome. An EXT1 result predicts group-level trends, not your personal course. Relatives who carry the identical change can differ widely, the type of change matters (missense carriers tend to have fewer growths than those with truncating changes), and each growth appears to need a second, local genetic hit before it forms. Your genotype tilts the odds; it does not seal them.

Cartilage Cancer Risk

A small but real lifetime risk in this condition is that one of the benign growths turns into chondrosarcoma, a cancer of cartilage, usually reported in about 1 to 5 percent of patients. Whether EXT1 specifically raises this risk more than EXT2 is unsettled: some reports link EXT1 to malignant change, but the largest cohort examined here did not confirm an independent effect. Practically, a growth that becomes painful or starts enlarging after you have finished growing deserves prompt evaluation regardless of which gene is involved.

A One-Time Result You Act On for Years

Because this is a fixed germline genotype, you never need to repeat the test to track a trend. There is nothing to trend. The result is permanent, and its worth lies in feeding ongoing decisions rather than in retesting the gene.

What does warrant ongoing attention is your body, not the DNA. If you carry a pathogenic variant, the useful follow-up is clinical and imaging surveillance of known or symptomatic growths, with particular attention to any lesion that grows or becomes painful after skeletal maturity. Ask a specialist to set the right imaging cadence for your specific lesion pattern; the genotype simply establishes that this monitoring is worth doing.

What to Do With a Positive or Unexpected Result

A positive result is a starting point for a workup, not an endpoint. If the variant was called by a screening method, confirm it with a definitive sequencing method, and have a clinical geneticist classify it using your ancestry, family pattern, and symptoms. An orthopedic or skeletal specialist can then map your growths and plan surveillance.

Because the condition is autosomal dominant, a confirmed variant is also family information. Each child of a carrier has a 50 percent chance of inheriting the same change, and testing biological siblings and parents can clarify who else should be evaluated. A negative result in the face of a convincing clinical picture should prompt broadening the search rather than reassurance: deletion and duplication testing (a technique called MLPA that spots missing or extra chunks of a gene) catches changes that sequence-only testing misses, and a minority of look-alike cases trace to other genes such as PTPN11.

When a Genetic Result Can Mislead

• Panel coverage: the assay only detects the specific variants and variant types it is designed to find. A sequence-only test can miss large deletions or duplications, so a negative result does not fully rule out a change in this gene.
• Overcalled variants: some changes once labeled disease-causing in databases also turn up in people without the condition. Population frequency data suggest a number of previously reported variants were either misclassified or do not always cause disease.
• Ancestry effects: several rare changes cluster in specific populations, so comparing your result against a mismatched reference group can make a harmless variant look dangerous. Interpretation should account for your background.
• No family history: roughly one in five patients has no affected relatives, and new (de novo) changes are common, so a blank family tree does not exclude a real inherited variant when growths are present.